Global Blockbuster Oncology Brands Market Size Study, by Brands (Opdivo, Keytruda, Perjeta, Ibrance), by Treatment (Lung Cancer, Lymphoma, Breast Cancer), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other), and Regional Forecasts 2022-2032

February 2025 | 285 pages | ID: G21B88E9E3F5EN
Bizwit Research & Consulting LLP

Abstracts

The global blockbuster oncology brands market was valued at USD 40.8 billion in 2023 and is projected to grow with a healthy compound annual growth rate (CAGR) of 8.0% over the forecast period of 2024-2032. This substantial growth is attributed to a multitude of factors, including the increasing global incidence of various cancer types, advancements in oncology drug development, and robust demand for novel therapeutic solutions. Blockbuster oncology drugs, often generating annual sales exceeding USD 1 billion, continue to dominate the oncology space, presenting lucrative opportunities for pharmaceutical companies.

The proliferation of cutting-edge treatments such as targeted immunotherapy, monoclonal antibodies, CAR-T cell therapies, and precision oncology drugs has significantly transformed cancer treatment protocols, providing tailored approaches based on tumor profiling and genetic insights. The favorable regulatory environment, including accelerated drug approvals from the FDA and EMA, coupled with enhanced reimbursement policies, is further bolstering market growth. Additionally, rising healthcare spending in emerging economies, coupled with increasing investments in research and development, is expected to propel innovation in oncology drugs.

The escalating prevalence of cancer across demographics is another critical growth driver. The International Agency for Research on Cancer (IARC) predicts that the number of global cancer cases will rise from 20 million in 2022 to over 35 million by 2050. This growing disease burden necessitates the adoption of advanced therapeutic solutions. Moreover, the pharmaceutical industry's commitment to meeting this demand is evident from substantial investments in clinical trials, partnerships, and technological advancements.

The competitive landscape of the blockbuster oncology brands market is characterized by innovation-driven strategies. Major players are leveraging collaborations, acquisitions, and pipeline advancements to secure leadership positions. Brands such as Opdivo and Keytruda have emerged as market leaders, supported by comprehensive clinical efficacy and broad-spectrum therapeutic applicability.

From a regional perspective, North America dominated the market in 2023, driven by high healthcare expenditure, strong adoption of advanced therapies, and a robust pharmaceutical ecosystem. However, the Asia Pacific region is poised to witness the fastest growth during the forecast period, supported by increasing healthcare infrastructure investments, government initiatives for cancer care, and a rising prevalence of the disease.

Major market player included in this report are:

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• AstraZeneca
• GSK plc
• Novartis AG
• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Amgen Inc.
• Eli Lilly and Company
• Genmab
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Sanofi

The detailed segments and sub-segment of the market are explained below:

By Brands

• Opdivo
• Keytruda
• Perjeta
• Ibrance
• Tecentriq
• Gazyva
• Tagrisso
• Darzalex
• Zejula
• Revlimid
• Imbruvica
• Others

By Treatment

• Lung Cancer
• Breast Cancer
• Multiple Myeloma
• Lymphoma
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

By Region: North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• China
• India
• Japan
• Australia
• South Korea
• Thailand

Latin America

• Brazil
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Years considered for the study are as follows:

• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET EXECUTIVE SUMMARY

1.1. Global Blockbuster Oncology Brands Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
  1.3.1. By Brands
  1.3.2. By Treatment
  1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
  2.3.1. Inclusion & Exclusion
  2.3.2. Limitations
  2.3.3. Supply Side Analysis
    2.3.3.1. Availability
    2.3.3.2. Infrastructure
    2.3.3.3. Regulatory Environment
    2.3.3.4. Market Competition
    2.3.3.5. Economic Viability (Consumer’s Perspective)
  2.3.4. Demand Side Analysis
    2.3.4.1. Regulatory Frameworks
    2.3.4.2. Technological Advancements
    2.3.4.3. Environmental Considerations
    2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET DYNAMICS

3.1. Market Drivers
  3.1.1. Rising Cancer Prevalence
  3.1.2. Advancements in Immunotherapies
  3.1.3. Increasing Healthcare Investments
3.2. Market Challenges
  3.2.1. High Cost of Cancer Treatments
  3.2.2. Limited Access in Emerging Economies
3.3. Market Opportunities
  3.3.1. Precision Oncology and Genomics
  3.3.2. Expansion in Emerging Markets
  3.3.3. Innovative Drug Delivery Technologies

CHAPTER 4. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Suppliers
  4.1.2. Bargaining Power of Buyers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s 5 Force Model
  4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
  4.2.1. Political
  4.2.2. Economic
  4.2.3. Social
  4.2.4. Technological
  4.2.5. Environmental
  4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET SIZE & FORECAST BY BRANDS 2022-2032

5.1. Segment Dashboard
5.2. Global Blockbuster Oncology Brands Market: By Brands Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  5.2.1. Opdivo
  5.2.2. Keytruda
  5.2.3. Perjeta
  5.2.4. Ibrance
  5.2.5. Others

CHAPTER 6. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET SIZE & FORECAST BY TREATMENT 2022-2032

6.1. Segment Dashboard
6.2. Global Blockbuster Oncology Brands Market: By Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  6.2.1. Lung Cancer
  6.2.2. Breast Cancer
  6.2.3. Multiple Myeloma
  6.2.4. Lymphoma
  6.2.5. Others

CHAPTER 7. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET SIZE & FORECAST BY DISTRIBUTION CHANNEL 2022-2032

7.1. Segment Dashboard
7.2. Global Blockbuster Oncology Brands Market: By Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  7.2.1. Hospital Pharmacy
  7.2.2. Retail Pharmacy
  7.2.3. Other

CHAPTER 8. GLOBAL BLOCKBUSTER ONCOLOGY BRANDS MARKET SIZE & FORECAST BY REGION 2022-2032

8.1. North America Blockbuster Oncology Brands Market
  8.1.1. U.S. Blockbuster Oncology Brands Market
  8.1.2. Canada Blockbuster Oncology Brands Market
  8.1.3. Mexico Blockbuster Oncology Brands Market
8.2. Europe Blockbuster Oncology Brands Market
  8.2.1. UK Blockbuster Oncology Brands Market
  8.2.2. Germany Blockbuster Oncology Brands Market
  8.2.3. France Blockbuster Oncology Brands Market
  8.2.4. Italy Blockbuster Oncology Brands Market
  8.2.5. Spain Blockbuster Oncology Brands Market
8.3. Asia Pacific Blockbuster Oncology Brands Market
  8.3.1. China Blockbuster Oncology Brands Market
  8.3.2. India Blockbuster Oncology Brands Market
  8.3.3. Japan Blockbuster Oncology Brands Market
  8.3.4. South Korea Blockbuster Oncology Brands Market
  8.3.5. Australia Blockbuster Oncology Brands Market
8.4. Latin America Blockbuster Oncology Brands Market
  8.4.1. Brazil Blockbuster Oncology Brands Market
  8.4.2. Argentina Blockbuster Oncology Brands Market
8.5. Middle East & Africa Blockbuster Oncology Brands Market
  8.5.1. Saudi Arabia Blockbuster Oncology Brands Market
  8.5.2. South Africa Blockbuster Oncology Brands Market
  8.5.3. UAE Blockbuster Oncology Brands Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis
  9.1.1. Bristol-Myers Squibb
  9.1.2. Merck & Co., Inc.
  9.1.3. AstraZeneca
9.2. Top Market Strategies
9.3. Company Profiles

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process
  10.1.1. Data Mining
  10.1.2. Analysis
  10.1.3. Market Estimation
  10.1.4. Validation
  10.1.5. Publishing
10.2. Research Attributes